Core Viewpoint - The company plans to acquire 100% equity of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xifeng Technology Co., Ltd. through cash transactions, with a total transaction price of 366 million RMB [1] Group 1 - The acquisition includes 1.58 billion RMB for Sanjian Qifa and 2.08 billion RMB for Xifeng [1] - The transaction is based on the valuation report provided by an asset appraisal agency [1] - After the acquisition, the company intends to increase the capital of Sanjian Qifa by 70 million RMB and Xifeng by 60 million RMB [1] Group 2 - The capital increase for Sanjian Qifa will consist of 22.15 million RMB added to registered capital and 47.84 million RMB to capital reserves [1] - For Xifeng, the capital increase will include 14.44 million RMB to registered capital and 45.56 million RMB to capital reserves [1]

Group 1 - The medical device sector increased by 0.19% on January 29, with Sanyou Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] - Key stocks in the medical device sector showed varied performance, with Sanyou Medical rising by 5.12% to a closing price of 22.60 [1] Group 2 - Major stocks that declined included Daan Gene, which fell by 9.96% to a closing price of 6.87, and Cap Bio, down 9.88% to 7.94 [2] - The medical device sector experienced a net outflow of 376 million yuan from institutional investors, while retail investors saw a net inflow of 201 million yuan [2][3] - Notable net inflows from retail investors were observed in stocks like Lepu Medical, which had a net inflow of 42.29 million yuan [3]

1月29日，华大智造涨5%，截至发稿，报69.30元/股，成交1.45亿元，换手率0.51%，总市值288.65亿 元。 资料显示，深圳华大智造科技股份有限公司位于广东省深圳市盐田区北山工业区综合楼及11栋2楼，成 立日期2016年4月13日，上市日期2022年9月9日，公司主营业务涉及专注于生命科学与生物技术领域,以 仪器设备、试剂耗材等相关产品的研发、生产和销售。主营业务收入构成为：销售仪器设备、试剂及耗 材90.89%，提供服务7.10%，其他(补充)2.01%。 从华大智造十大流通股东角度 数据显示，易方达基金旗下1只基金位居华大智造十大流通股东。易方达上证科创板50ETF（588080） 三季度减持109.79万股，持有股数752.58万股，占流通股的比例为1.82%。根据测算，今日浮盈赚取约 2483.52万元。 易方达上证科创板50ETF（588080）基金经理为林伟斌、成曦。 截至发稿，林伟斌累计任职时间12年333天，现任基金资产总规模1194.08亿元，任职期间最佳基金回报 82.52%， 任职期间最差基金回报-22.14%。 成曦累计任职时间9年270天，现任基金资产总规模2369.54 ...

Core Viewpoint - The company, BGI Genomics (stock code: 688114.SH), has released its earnings forecast for 2025, indicating a significant reduction in losses compared to the previous year, driven by operational improvements and favorable currency exchange impacts [2][4]. Financial Performance - The company expects a net profit attributable to shareholders of between -221 million to -273 million yuan for 2025, a notable improvement from a loss of 601 million yuan in the previous year, representing a year-on-year reduction of approximately 54.56% to 63.22% [4]. - After excluding non-recurring gains and losses, the anticipated net profit is projected to be between -322 million to -397 million yuan, compared to a loss of 653 million yuan last year, indicating a year-on-year improvement of about 39.18% to 50.67% [4]. Reasons for Performance Changes - The company has implemented measures focused on "quality improvement, efficiency enhancement, and return on investment," leading to a decrease in overall costs compared to the previous year [5]. - Currency exchange gains from holding foreign currency monetary items have increased due to fluctuations in the US dollar and euro [5]. - The company has reversed tax provisions related to previous years' uncertain tax disputes, resulting in a reduction in income tax expenses [5]. Company Overview - BGI Genomics is a domestic manufacturer focused on core tools and high-end equipment in life sciences, primarily engaged in gene sequencing and related laboratory automation equipment [6]. - The company emphasizes independent research and development, providing foundational technical equipment and systematic solutions for research institutions, clinical testing laboratories, and industrial clients [6]. Business Segments Gene Sequencing Business - The gene sequencing business is the core segment, continuously upgrading products and reagents to enhance sequencing efficiency, coverage, and application adaptability [7]. - In 2024, the company plans to launch the next-generation sequencing reagent StandardMPS 2.0, along with upgrades to several core sequencing platforms, enhancing their applicability across various research and clinical needs [9]. Laboratory Automation Business - The company is advancing towards systematic and intelligent upgrades in laboratory automation, focusing on key processes such as sample handling, experimental execution, and data analysis [10]. - New products like αLabStudio, αLabRobot, and αCube are being introduced to improve sample management efficiency and experimental stability [12]. New Business Segment - The new business segment focuses on multi-omics tools, ultrasound imaging, and intelligent robotics, aiming to meet cutting-edge research and clinical transformation needs [13][15]. - The company is expanding its capabilities in cell omics, spatiotemporal omics, and proteomics, enhancing high-throughput data collection and analysis [15][16].

●公司预计2 0 2 5年年度实现归属于母公司所有者的扣除非经常性损益的净利润- 3 9 , 7 0 0 . 0 0 万元 到- 3 2 , 2 0 0 . 0 0万元，与上年同期相比，亏损将减少2 5 , 5 7 0 . 6 8万元到亏损减少3 3 , 0 7 0 . 6 8万元， 同比亏损减少3 9 . 1 8%到亏损减少5 0 . 6 7%。 一、本期业绩预告情况 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近期，华大智造发布2 0 2 5年业绩预告。预告称2 0 2 5年亏损同比将减少5 0%以上： 重点内容提示 ●公司经初步测算，深圳华大智造科技股份有限公司（以下简称"公司"）预计2 0 2 5年年度实现 归属于母公司所有者的净利润与上年同期（法定披露数据）相比，实现归属于母公司所有者的 净 利 润- 2 7 , 3 0 0 . 0 0 万 元 到 - 2 2 , 1 0 0 . 0 0万元，与上年同期相比， 亏 损 将 减 少 3 2 , 7 8 2 . 7 0 万 元 到 亏 损减少3 7 , 9 8 2 . 7 0万元 ...

Group 1 - Spot gold price has surpassed $5000 per ounce for the first time, with institutions predicting it could rise to $6600 [2] - The recent surge in gold prices is attributed to U.S. President Trump's policies reshaping international relations and investors fleeing sovereign bonds and foreign exchange markets [2] - Last week, gold prices increased by 8.5%, driven by a weakening dollar, which has made gold and silver cheaper for global buyers [2] Group 2 - In the past two weeks, stock ETFs have seen a net outflow of nearly 500 billion yuan, with significant redemptions in broad-based ETFs [3] - The trading volume of stock ETFs has surged, with some broad-based ETFs reaching record highs since their inception [3] Group 3 - The semiconductor sector in A-shares has been active in mergers and acquisitions, with several companies announcing related plans and progress [8] Group 4 - The commercial aerospace sector is experiencing a talent shortage, with investors with relevant experience being highly sought after [9] - The market is facing a significant gap in experienced commercial aerospace investors, leading firms to recruit candidates with adjacent experience [9] Group 5 - Global commodity markets are entering a new super cycle, with fund managers strategically increasing allocations to non-ferrous and chemical products [10] - Factors such as global monetary expansion, a credit crisis in the dollar, and geopolitical conflicts are contributing to this anticipated cycle [10]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重点内容提示 ●公司经初步测算，深圳华大智造科技股份有限公司（以下简称"公司"）预计2025年年度实现归属于母 公司所有者的净利润与上年同期（法定披露数据）相比，实现归属于母公司所有者的净利润-27,300.00 万元到-22,100.00万元，与上年同期相比，亏损将减少32,782.70万元到亏损减少37,982.70万元，同比亏 损减少54.56%到亏损减少63.22%。 ●公司预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 -39,700.00万元 到-32,200.00万元，与上年同期相比，亏损将减少25,570.68万元到亏损减少33,070.68万元，同比亏损减 少39.18%到亏损减少50.67%。 证券代码：688114 证券简称：华大智造 公告编号：2026-001 深圳华大智造科技股份有限公司 2025年年度业绩预告 （二）业绩预告情况 1、经公司初步测算，预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据） 相比，实 ...

Core Viewpoint - The company, BGI Genomics, expects to report a net loss attributable to shareholders of the parent company ranging from -273 million to -221 million yuan for the year 2025, indicating a significant reduction in losses compared to the previous year [1] Financial Performance - The projected loss for 2025 represents a decrease in losses by 327.83 million to 379.83 million yuan compared to the previous year [1] - The year-on-year reduction in losses is estimated to be between 54.56% and 63.22% [1]

华大智造表示，报告期内，公司制定了一系列"提质增效重回报"措施，包括人效提升、研发聚焦、营销 费用全周期管理等措施，导致公司相关的成本费用相比同期减少。报告期内，由于汇率波动，导致公司 持有外币货币性项目产生的汇兑收益同比增加。此外，报告期内，上半年对以前年度涉及的不确定性的 税务争议风险相应的税务拨备进行冲回处理，导致所得税费用同比减少。根据企业会计准则及公司会计 政策等相关规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产计提了减值 准备的会计处理。 北京商报讯（记者 丁宁）1月25日晚间，华大智造（688114）发布2025年业绩预告显示，公司经初步测 算，预计2025年实现归属净利润与上年同期相比，实现归属净利润-2.21亿元到-2.73亿元，同比减亏3.28 亿元到3.8亿元，同比亏损减少54.56%到63.22%。 资料显示，华大智造专注于生命科学与生物技术领域仪器设备、试剂耗材等相关产品的研发、生产和销 售。2025年，公司把握生命科技多组学融合与AI深度赋能的双重浪潮，并推动公司在生命科学领域的 持续发展，将原基因测序仪业务、实验室自动化业务及新业务板块，整合为三大 ...

北京商报讯（记者 王蔓蕾）1月25日晚间，华大智造（688114）发布2025年年度业绩预告显示，经公司 初步测算，预计2025年年度实现归属净利润-2.73亿元至-2.21亿元，同比亏损减少54.56%—63.22%。 对于业绩变化的主要原因，华大智造表示，报告期内，公司制定了一系列"提质增效重回报"措施，包括 人效提升、研发聚焦、营销费用全周期管理等措施，导致公司相关的成本费用相比同期减少；由于美 元、欧元汇率波动，导致公司持有外币货币性项目产生的汇兑收益同比增加；上半年对以前年度涉及的 不确定性的税务争议风险相应的税务拨备进行冲回处理，导致所得税费用同比减少；根据企业会计准则 及公司会计政策等相关规定，基于谨慎性原则，公司对截至2025年12月31日合并报表范围内的各类资产 计提了减值准备的会计处理。 ...